Redefinition of myocardial infarction by a consensus dissenter: reply  by Alpert, Joseph S & Thygesen, Kristian
into a diagnostic classification which is comprehensive. They do
not cover early and other fatal cases, and nonfatal cases in which
tests are partial, delayed, missing or curtailed. Therefore, they are
not applicable to more than a proportion of coronary events in the
real world. New criteria need to be field tested and related either to
the current, or a modified version, of the International Statistical
Classification of Diseases and Health Problems (11) before they
are adopted, or there will be diagnostic confusion and chaos in
hospital and regional morbidity statistics. Comparative figures
could reflect the frequency and intensity of troponin measurement,
rather than the underlying disease burden.
None of this denies the immense value of the newer biochemical
markers such as troponins (12) in increasing the sensitivity and
specificity of diagnosis of coronary events; nor the consequent need
for older definitions and classifications to be revised for the modern
era, and for the purposes specified by the college presidents in their
accompanying editorial (1). The WHO MONICA Project criteria
were drafted 20 years ago (3) with strong transatlantic collabora-
tion to marry older European qualitative criteria (4), for classifying
myocardial infarction and coronary deaths, with American preci-
sion. These criteria mapped trends in coronary disease incidence
and case fatality across four continents for over a decade, in a third
of a million cases (9). It is time they were updated by those with
expertise in the field. The names of epidemiologists involved in
this recent “consensus” exercise have been used, while they them-
selves have been kept at arm’s length. Diagnosis means more than
recruitment to clinical trials. We are discussing among ourselves
how to carry the need for revised criteria forward from this brave
but flawed attempt. We hope to have the help of national and
international organizations.
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REPLY
We would like to thank Dr. Tunstall-Pedoe for his comments.
Controversy is the soul of all intellectual activities, and we welcome
Dr. Tunstall-Pedoe’s minority opinion concerning the recently
published consensus statement on the definition of myocardial
infarction. Unfortunately, Dr. Tunstall-Pedoe has seriously mis-
understood and misinterpreted both the nature of the European
Society of Cardiology/American College of Cardiology (ESC/
ACC) conference and the published document.
Dr. Tunstall-Pedoe was invited to participate in the meeting to
provide context for our discussions given his many years of
involvement with the original and subsequent modified World
Health Organization (WHO) definitions of myocardial infarction.
The conference was conceived as a joint project of the ESC and the
ACC with the hope that it would help to standardize the
definition of myocardial infarction in clinical studies, patient care
and health care statistics.
Procedure followed. The original participants at the first meeting
at the European Heart House created a first draft of the document.
Because of the large number of individuals involved (50) at this
first conference, a smaller number (6) were selected for further
work on the manuscript and its eventual report. It was never our
expectation that everyone in the medical community nor even
everyone at the original conference would be in total agreement
with the final report. We sought, therefore, to create a document
that would be accepted by most clinicians, investigators and
epidemiologists.
A first draft was sent to all participants, including Dr. Tunstall-
Pedoe. Anyone who responded to the first draft was sent subse-
quent drafts. Indeed, anyone who requested the then current draft
of the document received it by e-mail. The report went through 13
versions before the document was published. Dr. Tunstall-Pedoe
did not respond to the first draft that contained approximately 70%
of the material that was eventually published. Three other recog-
nized and widely published epidemiologists received all subsequent
drafts of the document and all their suggestions were incorporated
into the published report. The final manuscript was read and
critiqued by the Scientific and Clinical Initiative Committee of the
ESC, the Board of the ESC, selected leaders of the ACC and
selected reviewers.
Dr. Tunstall-Pedoe suggests that we should have sought input
from interest groups involved with rehabilitation, health promo-
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tion (whatever this refers to), employment and insurance. Indeed,
such individuals were invited to the conference as well as individ-
uals representing government, industry, and even the WHO.
Many of these groups responded and had input into the final
document.
Content of the revised definition of myocardial infarction. Dr.
Tunstall-Pedoe misinterprets the final document. In the report,
the definition of myocardial infarction rests on elevated blood
troponin or CK-MB levels in an appropriate clinical setting.
Patients who arrive at the hospital 24 or 48 h after the onset of
their infarct will still have an elevated troponin level that remains
abnormal for 3 to 14 days following the onset of myocardial
necrosis. Therefore, such late-arriving patients as described by Dr.
Tunstall-Pedoe will meet the new definition of myocardial infarc-
tion. Patients with infarction who are first seen many days, weeks
or months after their infarction can still meet the diagnosis for
“established infarction” as noted in the published ESC/ACC
document.
The patient who dies shortly after arriving in the coronary care
unit represents a problem for diagnosis of myocardial infarction.
This is true today and will remain true in the future. As pointed
out by the pathology group in the published ESC/ACC document,
infarction cannot be recognized pathologically until at least 6 h has
passed since the onset of ischemia/infarction. Thus, there is
currently a window of “blindness” for the diagnosis of infarction
that lasts for approximately 6 h after the onset of myocardial
necrosis. Abnormal CK-MB levels may be seen as early as 3 to 4 h
after the onset of necrosis and abnormal blood myoglobin levels
may be observed even earlier. Perhaps, subsequent revised editions
of the ESC/ACC report will contain suggestions about diagnosis
of infarction in the early few hours after the onset of myocardial
necrosis. Further data will be needed before any such suggestion
can be made. In addition, patients with unequivocal ECG evidence
(pathologic Q-waves) for infarction but no serological assays can
still be labeled as having had an infarct based on the criteria for
“established infarction.”
Even though the enzyme assays are not standardized in the
original WHO and derived MONICA criteria, Dr. Tunstall-
Pedoe vigorously defends the MONICA definition for the diag-
nosis of myocardial infarction (1). This is understandable, but may
be ill-advised given the recent report of Porela et al. (2) that failed
to document prognostic significance associated with this method
for diagnosing infarction. Indeed, Dr. Tunstall-Pedoe states that
the MONICA investigators have been seriously considering revis-
ing their own definition of myocardial infarction. This is com-
mendable given the recently published data cited above.
We welcome Dr. Tunstall-Pedoe’s suggestion that the new
definition be “field tested,” and indeed, a number of investigators
are already proceeding with such studies. As noted already, the
data of Porela et al. (2) support the concept of myocardial
infarction defined by means of abnormal blood levels of a myo-
cardial enzyme, CK-MB. These same investigators failed to find
similar supportive data for the MONICA definition of infarction.
We anxiously await the results of further “field testing.”
The unfortunate fact is that the “new” definition of myocardial
infarction was already being widely used before our meeting in
Nice, France, took place. Indeed, many hospitals and many
clinicians around the world already define myocardial infarction
based on an abnormal blood troponin value. It was this fact, and
the resulting confusion created between hospitals and physicians
who used the new sensitive and specific cardiac markers versus
those who did not, that led us to organize the ESC/ACC
consensus conference. Thus, the “confusion and chaos” referred to
by Dr. Tunstall-Pedoe were already present when we began
sending out invitations to the meeting at the European Heart
House.
In conclusion, we believe that the process as well as the product
that led to the ESC/ACC new definition for myocardial infarction
were both fair, reasonable and represented the opinion of most of
the participants at the ESC/ACC conference as well as a variety of
experts who subsequently examined the manuscript and made
useful comments. We look forward to further work in this area that
will undoubtedly result in revisions to the currently recommended
definition for myocardial infarction.
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Benefit of Aspirin Plus
Angiotensin-Converting Enzyme Inhibitor
The conclusions of your recent editorial commentary (1) on a
meta-analysis (2) of the trials of angiotensin-converting enzyme
(ACE) inhibitors in acute myocardial infarction (MI) go far
beyond the randomized evidence and could well be mistaken. As
treatments for acute MI, aspirin substantially improves survival (3)
and ACE inhibitors moderately improve survival (2,4). The trials
of aspirin were done at a time when ACE inhibitors were not
routinely used in acute MI, and demonstrated the substantial
effectiveness of aspirin. The trials of ACE inhibitors were done
more recently, at a time when aspirin was already widely used in
acute MI, and the meta-analysis of their results showed that the
addition of ACE inhibitors produced a small but significant
additional benefit: that is, that aspirin 1 ACE inhibitors produce
slightly better survival than aspirin alone (2). It was concluded that
aspirin is of value in the treatment of acute MI, and that the
combination of aspirin 1 ACE inhibitors is slightly but signifi-
cantly better than aspirin alone. A similar conclusion was sug-
gested by meta-analyses of the trials of long-term aspirin therapy
(3) and of the trials of long-term ACE inhibitor therapy (5);
aspirin is of value, but the combination of aspirin 1 ACE
inhibitors is somewhat better than aspirin alone.
In the trials of ACE inhibitors both during and after MI, there
was no significant interaction between the presence of aspirin and
the efficacy of ACE inhibitors (2,5), and it was a bizarre non-
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